How Kisho Compares
The only rare disease intelligence platform combining comprehensive data, real-time news, policy tracking, and a developer-friendly API — all grounded in open science.
The Landscape at a Glance
How Kisho compares across 10 dimensions that matter to enterprise buyers, developers, and healthcare organizations.
| Dimension | Kisho | Patient Advocacy Databases | Pharma Intelligence Platforms | AI Health Assistants | Government & Open Databases | Real-World Data Platforms |
|---|---|---|---|---|---|---|
| Rare disease coverage | 15,964 diseases | 1,200–6,500 | 120–2,300 markets | Not specialized | ~6,500 (fragmented) | Not disease-focused |
| Structured API | 18+ endpoints | Enterprise only | General-purpose | No unified API | Enterprise only | |
| Self-serve pricing | From $0 (free tier) | Free (no API) | $50K–200K+/yr | Per-token API | Free (no API) | $50K–500K+/yr |
| Patient-friendly content | 7 report sections | Limited diseases | General medical | Limited | ||
| News intelligence | 25+ sources, AI-classified | Limited | ||||
| Policy tracking | 50-state, AI-classified | |||||
| Data transparency | Open science (MONDO, HPO) | Varies | Proprietary | Black box | Open but fragmented | Proprietary |
| QC validation pipeline | 3-tier + HGNC + fact-check | Editorial review | Analyst review | None (disclaimers) | Expert curation | N/A |
| Expert stewardship | Named stewards | N/A | Analyst reports | Gov. experts | ||
| Time to deploy | Days | N/A (no API) | Months | Days (general) | DIY assembly | Months |
Comparison based on publicly available information as of February 2026. Categories represent typical capabilities within each platform type.
What Sets Kisho Apart
Six structural advantages that no single competitor replicates.
15,964
rare diseases
Unmatched Disease Coverage
Built on the MONDO Disease Ontology — the most comprehensive open disease classification available. 2.5x to 13x more rare disease coverage than alternative platforms, with 7,400+ diseases featuring patient-ready AI reports.
10+
authoritative sources
Open Science Transparency
Every claim traces to a named, verifiable source: MONDO, HPO, HGNC, FDA, ClinicalTrials.gov, PubMed, and more. Every report includes an evidence base indicator so you always know how well-documented a disease is.
$0
to start (free tier)
Developer-First API
Full REST API with 18+ endpoints, OpenAPI 3.0 spec, and a free tier. Deploy in days, not months of contract negotiation. Self-serve pricing from $500/month — orders of magnitude less than enterprise-only alternatives.
6
data dimensions unified
Connected Intelligence
The only platform connecting disease content, real-time news (25+ sources), policy tracking (50 states), clinical trials, FDA drugs, patient groups, and assistance programs in a single API.
>99%
gene hallucination detection
QC-Validated Content
Every report passes through a 3-tier validation pipeline with 15+ automated rules, HGNC gene symbol validation (44,748 symbols), and fact-checking against source data. Content that fails validation is quarantined — never published.
Named
accountability
Expert Stewardship
Verified clinicians, researchers, and genetic counselors claim disease reports and stand behind their validation publicly. Combined with community contributions, AI moderation, and complete version history.
Common Questions
Questions enterprise buyers ask when evaluating rare disease data options.
“Can’t we just use a general AI assistant for rare disease content?”
General AI assistants are not specialized in rare diseases, do not offer structured APIs for disease-specific data, and explicitly disclaim clinical use. Kisho’s content is synthesized exclusively from 10+ authoritative sources and validated through a 3-tier QC pipeline before publication — with every claim traceable to its source.
“Why pay when free databases exist?”
Free databases are invaluable for individual lookups. But they do not offer a unified API, real-time news intelligence, policy tracking, or QC-validated content at scale. If you are building a product that needs structured rare disease data, you need an API — not a collection of websites to query manually.
“We already have a pharma intelligence subscription.”
Pharma intelligence platforms excel at drug pipeline data. But they do not provide patient-friendly disease content, AI-classified news, patient group directories, or assistance program databases. Kisho is complementary — it adds the patient and community intelligence layer that pipeline-focused platforms miss.
“What about building disease content in-house?”
At approximately $250 per report (medical writer rate), covering 15,964 diseases would cost $4M+ and take years. Kisho delivers the same breadth for $6,000/year via API — with ongoing freshness, QC validation, and news intelligence included.
The Cost of Building It Yourself
Rare disease content at scale has historically required large teams and long timelines. Kisho changes the economics.
Approach | Cost | Time to Deploy | Coverage |
|---|---|---|---|
| Medical writer team | $123,500 | 12+ months | ~500 diseases |
| Content agency | $875,000+ | 18+ months | ~250 diseases |
| In-house data team | $245,000+/yr | 6+ months setup | Variable |
| Kisho API | $6,000/yr | Days | 15,964+ diseases |
Cost estimates based on industry averages for medical content creation. Kisho API pricing reflects the self-serve tier at $500/month billed annually.
Ready to See It in Action?
Explore our disease reports, browse the API documentation, or talk to our team about how Kisho can power your rare disease data needs.